Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.
Crupi MJF, Taha Z, Janssen TJA, Petryk J, Boulton S, Alluqmani N, Jirovec A, Kassas O, Khan ST, Vallati S, Lee E, Huang BZ, Huh M, Pikor L, He X, Marius R, Austin B, Duong J, Pelin A, Neault S, Azad T, Breitbach CJ, Stojdl DF, Burgess MF, McComb S, Auer R, Diallo JS, Ilkow CS, Bell JC. Crupi MJF, et al. Among authors: mccomb s. Front Immunol. 2022 Nov 3;13:1029269. doi: 10.3389/fimmu.2022.1029269. eCollection 2022. Front Immunol. 2022. PMID: 36405739 Free PMC article.
Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy.
Kilgour MK, Bastin DJ, Lee SH, Ardolino M, McComb S, Visram A. Kilgour MK, et al. Among authors: mccomb s. Front Immunol. 2023 May 2;14:1166038. doi: 10.3389/fimmu.2023.1166038. eCollection 2023. Front Immunol. 2023. PMID: 37205115 Free PMC article. Review.
Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapy.
Taha Z, Crupi MJF, Alluqmani N, MacKenzie D, Vallati S, Whelan JT, Fareez F, Alwithenani A, Petryk J, Chen A, Spinelli MM, Ng K, Sobh J, de Souza CT, Bharadwa PR, Lee TKH, Thomas DA, Huang BZ, Kassas O, Poutou J, Gilchrist VH, Boulton S, Thomson M, Marius R, Hooshyar M, McComb S, Arulanandam R, Ilkow CS, Bell JC, Diallo JS. Taha Z, et al. Among authors: mccomb s. Nat Commun. 2024 Aug 23;15(1):7267. doi: 10.1038/s41467-024-51498-0. Nat Commun. 2024. PMID: 39179564 Free PMC article.
Efficacy of chimeric antigen receptor engineered natural killer cells in the treatment of hematologic malignancies: a systematic review and meta-analysis of preclinical studies.
Bastin DJ, Kilgour MK, Shorr R, Sabri E, Delluc A, Ardolino M, McComb S, Lee SH, Allan D, Ramsay T, Visram A. Bastin DJ, et al. Among authors: mccomb s. Cytotherapy. 2024 Nov 23:S1465-3249(24)00928-9. doi: 10.1016/j.jcyt.2024.11.004. Online ahead of print. Cytotherapy. 2024. PMID: 39692673
A High-Throughput Method for Characterizing Novel Chimeric Antigen Receptors in Jurkat Cells.
Bloemberg D, Nguyen T, MacLean S, Zafer A, Gadoury C, Gurnani K, Chattopadhyay A, Ash J, Lippens J, Harcus D, Pagé M, Fortin A, Pon RA, Gilbert R, Marcil A, Weeratna RD, McComb S. Bloemberg D, et al. Among authors: mccomb s. Mol Ther Methods Clin Dev. 2020 Jan 31;16:238-254. doi: 10.1016/j.omtm.2020.01.012. eCollection 2020 Mar 13. Mol Ther Methods Clin Dev. 2020. PMID: 32083149 Free PMC article.
Application of blood brain barrier models in pre-clinical assessment of glioblastoma-targeting CAR-T based immunotherapies.
Huang J, Li YB, Charlebois C, Nguyen T, Liu Z, Bloemberg D, Zafer A, Baumann E, Sodja C, Leclerc S, Fewell G, Liu Q, Prabhakarpandian B, McComb S, Stanimirovic DB, Jezierski A. Huang J, et al. Among authors: mccomb s. Fluids Barriers CNS. 2022 Jun 1;19(1):38. doi: 10.1186/s12987-022-00342-y. Fluids Barriers CNS. 2022. PMID: 35650594 Free PMC article.
93 results